Oxymetholone in aplastic anaemia

Ma, Minghong; Delamore, I. W.

doi:10.1136/pgmj.50.581.166

Cited by 4 publications

(3 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Many studies have presented OS ranging from 41 to 65% over two to five years. [14][15][16] In this study, with the median follow up time of 2.7 years, 48.6% OS was observed. The SAA/vSAA group had a lower OS, and shorter median time as well.…”

Section: Discussionsupporting

confidence: 47%

“… 13 ANC <5 x 10 9 /L was presented as a factor influencing mortality. 16 On multivariable analysis, we did not find significant differences between ANC <5 x 10 9 /L and ANC ≥5 x 10 9 /L. Undetectable association between neutrophil count and mortality could have been affected by the small sample size which was one of our limitations.…”

Section: Discussionmentioning

confidence: 62%

“…Androgens were forced to be used as monotherapy in limited resources countries and the efficacy of these agents was evaluated among patients with AA. 8 , [14][15][16] The response of oxymetholone was reported as 10% and 56% for SAA/vSAA and nSAA, respectively. 8 Among responders, most patients responded to oxymetholone after six months of treatment.…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis

Pengthina¹,

Saelue²

2022

JBM

View full text Add to dashboard Cite

Background Bone marrow transplantation, antithymocyte globulin/cyclosporine and eltrombopag are recommended as first-line therapy of severe aplastic anemia (SAA). However, androgens could be considered as front-line treatment among any patients ineligible for better methods although unsatisfactory efficacy is presented. Objective This retrospective study aimed to evaluate response and survival rate of practical-based treatment with oxymetholone. Patients and Methods This constituted an analysis of patients receiving a diagnosis of acquired aplastic anemia (AA) at the age of 15 or over and receiving oxymetholone between January 2004 and December 2018. Propensity Score Analysis (PSA) 1:1 matching was performed, according to sex, age and interval from first symptom to treatment. The primary outcome was one-year overall response (OR). Results Seventy-four patients were successfully matched by PSA. The 1-year OR of oxymetholone in the nonsevere AA (nSAA) and SAA/very severe AA (vSAA) groups was 54.1 and 13.5%, respectively (P <0.001). With median follow-up 2.7 years, the overall survival was 59.5% in nSAA and 37.8% in SAA/vSAA (P = 0.051). Median survival in nSAA and SAA/vSAA were 7.0 years and 1.8 years, respectively (P = 0.045). However, the responders of SAA/vSAA had longer survival than nonresponders of the nSAA group. Conclusion These results revealed longer survival among the responders of patients with AA, even in the SAA/vSAA group. However, close monitoring of therapeutic responses is still performed. Switching therapy is necessary when remission is undetected after 6 months of oxymetholone treatment.

show abstract

Section: Discussionsupporting

confidence: 47%

Section: Discussionmentioning

confidence: 62%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis

Pengthina¹,

Saelue²

2022

JBM

View full text Add to dashboard Cite

show abstract

Preconcentration and spectrophotometric determination of oxymetholone in the presence of its main metabolite (mestanolone) using modified maghemite nanoparticles in urine sample

Madrakian

Afkhami

Rahimi

et al. 2013

Talanta

View full text Add to dashboard Cite

Androgen Therapy of Aplastic Anaemia ‐A Prospective Study of 352 Cases

Najean

Pecking

Danvic

1979

Scandinavian Journal of Haematology

View full text Add to dashboard Cite

A prospective study of 352 patients with aplastic anaemia on androgen therapy has been performed. The following main observations have been obtained: The actuarial mortality rate at the 20th month is 52 %, half the deaths being observed during the first 3 months; these figures are similar to those previously published, from smaller series of androgen‐treated patients, and lower than those of non‐androgen‐treated cases. Differences in survival and improvement were observed between groups of patients treated for more than 3 months with either alkylated or non‐alkylated drugs. Signs of liver damage were observed no matter which was the drug used. Continous improvement can be observed even in the 2nd year of treatment indicating that full‐dose androgen therapy should be continued up to 20 months in not fully improved patients. The degree of initial disease activity is a clear prognostic parameter for the mortality in the first quarter of the course. In case of survival of severe cases, improvement can be obtained to the same extent as in milder cases. This stress the need for adequate maintenance therapy in all types of patients. Addition of glucocorticoids harms the prognosis, mainly in most granulocytopenic patients. Glucocorticoids have no effect upon the liver damage induced by andro‐gens.

show abstract

Oxymetholone in aplastic anaemia

Cited by 4 publications

References 21 publications

Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis

Efficacy of Oxymetholone in Severe and Nonsevere Acquired Aplastic Anemia: A Propensity Score Matching Analysis

Preconcentration and spectrophotometric determination of oxymetholone in the presence of its main metabolite (mestanolone) using modified maghemite nanoparticles in urine sample

Androgen Therapy of Aplastic Anaemia ‐A Prospective Study of 352 Cases

Contact Info

Product

Resources

About